NCT06520891 "The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
| NCT ID | NCT06520891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fayoum University |
| Condition | 2 Drugs Are Statin and SGLT2i |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2024-06-01 with a primary completion date of 2025-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)
Eligibility Criteria
Inclusion Criteria: * we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease, * They assessed the use of statin with SGLT2i. Exclusion Criteria: * We exclude patients with 1. liver dysfunction. 2. renal dysfunction. 3. fungal infection. 4. coagulation disorder. 5. Pts using drugs that interact with SGLT2i. 6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06520891 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying 2 Drugs Are Statin and SGLT2i. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06520891 currently recruiting?
Yes, NCT06520891 is actively recruiting participants. Contact the research team at Raghda.hussien@pharm.bsu.edu.eg for enrollment information.
Where is the NCT06520891 trial being conducted?
This trial is being conducted at Al Fayyum, Egypt.
Who is sponsoring the NCT06520891 clinical trial?
NCT06520891 is sponsored by Fayoum University. The trial plans to enroll 90 participants.